Boston Financial Mangement LLC Sells 1,111 Shares of CVS Health Co. (NYSE:CVS)

Boston Financial Mangement LLC trimmed its position in CVS Health Co. (NYSE:CVS) by 18.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,034 shares of the pharmacy operator’s stock after selling 1,111 shares during the quarter. Boston Financial Mangement LLC’s holdings in CVS Health were worth $226,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CVS. MidAtlantic Capital Management Inc. bought a new stake in CVS Health during the third quarter worth approximately $25,000. Ridgewood Investments LLC increased its stake in CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 450 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in CVS Health during the fourth quarter worth approximately $28,000. Legacy Investment Solutions LLC bought a new stake in CVS Health during the third quarter worth approximately $31,000. Finally, Reston Wealth Management LLC bought a new stake in CVS Health during the third quarter worth approximately $32,000. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Down 1.8 %

CVS Health stock opened at $65.20 on Friday. The business has a fifty day moving average of $52.11 and a two-hundred day moving average of $56.18. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The firm has a market cap of $82.21 billion, a P/E ratio of 17.81, a P/E/G ratio of 0.98 and a beta of 0.61. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts forecast that CVS Health Co. will post 5.91 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.08%. The ex-dividend date was Thursday, January 23rd. CVS Health’s payout ratio is presently 72.68%.

Insider Transactions at CVS Health

In other news, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of analyst reports. Barclays upped their target price on CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and upped their target price for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Royal Bank of Canada cut their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Wolfe Research boosted their price target on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, Piper Sandler lowered their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a report on Monday, November 25th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $70.00.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.